Cost-utility analysis of expanding the colorectal cancer screening policy in Flanders
Public Health · 2024
DOI: 10.1016/j.puhe.2024.03.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health, 2024. Verfasst von M Lelie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vrije Universiteit Brussels, Belgium. Electronic address: max.lelie@vub.be. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cost-Benefit Analysis, Quality-Adjusted Life Years, Early Detection of Cancer. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Vlaamse regering, Vlaamse overheid.
Abstract (Originalsprache)
OBJECTIVE: Since 2013, Flanders has introduced a screening programme for colorectal cancer for all citizens aged between 50 and 74 years. The objective of this study was to assess the cost-utility of an expansion of the colorectal cancer screening policy in Flanders (Belgium) and to place these findings in the international context. METHODS: Cost-utility analysis using high-detail data about screening participation, screening results, and epidemiological data, a Markov cohort model has been constructed to study long-term costs and effects. A cost-utility analysis was performed as a three-way comparison between current, expanded (from age 45 years), and no screening scenarios, from a societal and healthcare perspective. Robustness was assessed by both one-way and probabilistic sensitivity analyses. RESULTS: Analyses show that both current and expanded screening result in quality-adjusted life years (QALY) gains and are mostly cost-saving. Overall, 97.5% of Incremental Cost-Effectiveness Ratios (ICERs) remained well below € 2000 per QALY for all comparisons. Parameters related to the colonoscopy that follows a positive test result such as compliance and cost are especially impactful on the cost-effectiveness. CONCLUSIONS: Screening participation and screening costs have remained comparatively stable, making colorectal cancer screening a cost-effective (dominant) policy. Expanding the screen age to 45 years is also cost-effective (dominant) compared with current screening, albeit with a slimmer margin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vrije Universiteit Brussels, Belgium. Electronic address: max.lelie@vub.be.
- Vrije Universiteit Brussels, Belgium.
- KU Leuven, Belgium.
- University of Ghent, Belgium.
Förderung
- Vlaamse regering
- Vlaamse overheid
Zitieren
APA
Lelie, M., Parmentier, R., Simoens, S., Annemans, L., & Putman, K. (2024). Cost-utility analysis of expanding the colorectal cancer screening policy in Flanders. Public Health. https://doi.org/10.1016/j.puhe.2024.03.020
Vancouver
Lelie M, Parmentier R, Simoens S, Annemans L, Putman K. Cost-utility analysis of expanding the colorectal cancer screening policy in Flanders. Public Health. 2024. doi:10.1016/j.puhe.2024.03.020
BibTeX
@article{Lelie2024,
author = {Lelie, M and Parmentier, R and Simoens, S and Annemans, L and Putman, K},
title = {Cost-utility analysis of expanding the colorectal cancer screening policy in Flanders},
journal = {Public Health},
year = {2024},
doi = {10.1016/j.puhe.2024.03.020}
}
EUVIMED